Cipla enters into binding term sheet to establish JV Company in Algeria

13 Feb 2015 Evaluate

Cipla has entered into a binding term sheet with its existing partner, Biopharm SPA, for establishing a joint venture (JV) company in Algeria. The JV Company will manufacture and market respiratory products facilitating Cipla’s front-end presence in Algeria.

As per the term sheet, the company’s wholly owned subsidiary, Cipla (EU), will hold a 40% stake in the JV Company while the remainder will be held by a Biopharm-led Algerian consortium. The JV Company is expected to make an investment of up to $15 million in the construction of a manufacturing facility. Cipla (EU) initial investment in cash in the JV Company is expected to be $6 million.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1328.25 15.40 (1.17%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×